Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular and renal protective benefits independent of their blood glucose-lowering effects, making them suitable for treating heart failure and chronic kidney disease in diabetic patients.
If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga) or GLP-1 agonists (like Ozempic or Trulicity). These drugs not only help control blood sugar but also protect your heart and kidneys, which is often more important than just lowering the number on the glucose meter.
StrongSupportsVERY_HIGH confidence
SGLT2 inhibitors and GLP-1 receptor agonists not only improve glycemic control but also offer cardiovascular and renal protective effects, making them direct therapeutic options for these conditions.
Why this rating
Supported by multiple large, landmark randomized controlled trials (EMPA-REG, DAPA-HF, LEADER, etc.).
Source
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Jong Han Choi et al. · Public Health Weekly Report · 2024
DOI 10.56786/phwr.2024.17.44.4
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Early combination therapy using low-hypoglycemia-risk agents (e.g., SGLT2 inhibitors or GLP-1 receptor agonists) combined with metformin at diagnosis is more effective than sequential stepwise therapy at maintaining glycemic targets and minimizing diabetes-related complications.Good
- Continuous Glucose Monitoring (CGM) and automated insulin delivery systems significantly improve glycemic control accuracy, reduce hypoglycemia risk, and enhance treatment adherence in patients with Type 1 Diabetes and insulin-treated Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →